Fluid-Cooled Radiofrequency Ablation Market Report 2025

The fluid-cooled radiofrequency ablation market size has grown strongly in recent years. It will grow from $2.55 billion in 2024 to $2.79 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth observed during the historic period can be attributed to the increasing incidence of cancer-related bone metastases, heightened awareness among physicians and patients, rising demand for outpatient procedures, an expanding geriatric population, and greater integration of imaging and navigation technologies.

The fluid-cooled radiofrequency ablation market size is expected to see strong growth in the next few years. It will grow to $3.98 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The projected growth in the forecast period can be linked to the rising number of trained interventional radiologists and pain specialists, the expansion of hospital and specialty clinic capacity, increased utilization in spinal pain and facet joint treatments, intensifying competition among medical device manufacturers, and growing patient preference for non-pharmacological pain management. Key trends expected during the forecast period include advancements in internally cooled electrode designs, incorporation of real-time temperature and impedance monitoring, innovations in catheter-based delivery systems, improvements in feedback-controlled ablation technologies, and technological convergence with robotic-assisted surgical platforms.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the fluid-cooled radiofrequency ablation market in the coming years. Chronic diseases are long-term health conditions that generally last for a year or more, requiring continuous medical attention and sometimes restricting daily activities. The rise in chronic diseases is largely due to the aging population, as older individuals are more susceptible to prolonged health issues. Fluid-cooled radiofrequency ablation aids in managing these conditions by applying precise heat to nerve tissues to block pain signals, offering long-term relief for ailments such as chronic back pain and arthritis. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australian government agency, chronic obstructive pulmonary disease (COPD) was responsible for 7,691 deaths in 2022, or 29.6 per 100,000 population, accounting for 4% of all deaths. Consequently, the growing prevalence of chronic diseases is contributing to the expansion of the fluid-cooled radiofrequency ablation market.

Companies operating in the fluid-cooled radiofrequency ablation market are concentrating on introducing innovative products, such as internally cooled radiofrequency ablation systems, to improve heat dissipation, enhance procedural accuracy, and reduce damage to nearby healthy tissues. Internally cooled radiofrequency ablation systems are medical devices that transmit RF energy to ablate tissue while circulating fluid inside the electrode to prevent overheating and allow deeper, more effective treatment. In March 2024, Medtronic Plc obtained FDA 510(k) clearance for its OsteoCool 2 bone tumor ablation system, designed to enhance the treatment of painful bone tumors with improved precision and efficiency. This system enables the simultaneous use of four internally cooled probes, facilitating the ablation of multiple vertebral bodies or the creation of larger ablation zones. Delivering 20 watts per channel, it is the most powerful bone tumor ablation system available, increasing tumor destruction efficiency. Its internal water-cooling feature ensures consistent ablations while minimizing the risk of overheating surrounding tissues, making the procedure safer. The OsteoCool 2 is intended to provide effective pain relief and palliative care for malignant bone metastases and benign tumors, such as osteoid osteoma, improving patient outcomes through minimally invasive techniques.

In August 2022, Medtronic plc, an Ireland-based medical device company, acquired Affera, Inc. for an undisclosed amount. This acquisition aims to strengthen Medtronic’s cardiac ablation portfolio by entering the advanced cardiac mapping and navigation segment, offering integrated solutions to improve arrhythmia treatment outcomes and solidify its market position. Affera, Inc. is a US-based medical device company specializing in fluid-cooled radiofrequency ablation.

Major players in the fluid-cooled radiofrequency ablation market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, CONMED Corporation, Lepu Medical Technology, MicroPort Scientific Corporation, Avanos Medical, Japan Lifeline Co. Ltd., AtriCure Inc, AngioDynamics, SyMap Medical, CardioFocus Inc, Imricor Medical Systems Inc., Stereotaxis Inc., Autonomix Medical, Innoblative Designs Inc, livetec Ingenieurbüro GmbH.

North America was the largest region in the fluid-cooled radiofrequency ablation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fluid-cooled radiofrequency ablation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fluid-cooled radiofrequency ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Fluid-cooled radiofrequency ablation is a medical technique that employs internally cooled electrodes to deliver controlled heat for accurate tissue ablation, most commonly in the treatment of cardiac arrhythmias or tumors. This method involves circulating fluid within the electrode to cool its tip, enabling deeper and more regulated thermal energy delivery for effective ablation of targeted tissue.

The primary categories of fluid-cooled radiofrequency ablation include radiofrequency ablation devices, accessory components, and fluid-cooling systems. Radiofrequency ablation (RFA) devices are specialized medical instruments that utilize high-frequency electrical energy to produce heat and eliminate targeted abnormal tissues for therapeutic purposes. These devices often incorporate advanced features such as integrated imaging and real-time feedback systems. The targeted tissues generally include solid tumors, soft tissue tumors, and bone tumors. These systems are applied across multiple medical specialties, including cardiology, oncology, pain management, and urology, and are frequently used in hospitals, ambulatory surgical centers, specialty clinics, and other healthcare facilities.

The fluid-cooled radiofrequency ablation market research report is one of a series of new reports that provides fluid-cooled radiofrequency ablation market statistics, including fluid-cooled radiofrequency ablation industry global market size, regional shares, competitors with a fluid-cooled radiofrequency ablation market share, detailed fluid-cooled radiofrequency ablation market segments, market trends and opportunities, and any further data you may need to thrive in the fluid-cooled radiofrequency ablation industry. This fluid-cooled radiofrequency ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluid-cooled radiofrequency ablation market consists of revenues earned by entities providing services such as cardiac arrhythmia treatment, tumor ablation therapy, pain management procedures, pulmonary vein isolation, and clinical training and device support. The market value includes the value of related goods sold by the service provider or included within the service offering. The fluid-cooled radiofrequency ablation market also includes sales of products such as radiofrequency generators, cooled ablation catheters, irrigation pumps, temperature monitoring systems, and electrode cables. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.